Realyze Intelligence

Meet Mel Mann, MBA, M.Ed - who, when diagnosed with terminal chronic myeloid leukemia (CML) in 1995, "saw a clinical trial as a chance to get tomorrow’s medicine today." Fast forward 26 years - Mel is a 26-year cancer survivor & is living proof of the life-changing power of clinical trials. He credits Dr. Druker and the life-saving drug he developed, Gleevec, for allowing him to see his daughter grow up and become a physician. At Realyze Intelligence, we harness clinician-trained-AI to empower cancer care sites to screen ALL patients for clinical trials that they may qualify for, ensuring more people like Mel can access cutting-edge treatments. We want patients to have more. More birthdays. More weddings. More graduations. More memories. More Mondays. Read more about Mel's Story https://lnkd.in/gtajzara #ClinicalTrials #CancerResearch #AIOncology #AIinPrecisionOncology #ClinicalTrialsForAll #NoMoreZombieTrials #RealyzeIntelligence

📰 ⚡ Friday Newsflash ⚡📰 The American Society of Clinical Oncology (ASCO) Post has shared more about the recently published JAMA Surgery study where Realyze Intelligence technology is used to transform clinical data into actionable insights that directly improve breast cancer patient outcomes. We're so proud to be part of a study that illustrates how AI can be harnessed to empower clinicians with real-world-data insights that enable personalized care. This study is the result of multidisciplinary collaboration between UPMC Hillman Cancer Center, Institute for Precision Medicine, Magee-Womens Research Institute & Foundation and the University of Pittsburgh -- kudos to this cross functional team for using innovative tech for the benefit of patients! https://lnkd.in/gkfa3mCn #AIOncology #AIinPrecisionOncology #AIforGood #ClinicalTrialsforAll #BreastCancerInnovation #RealyzeIntelligence

Priscilla F. McAuliffe, MD, PhD, associate professor of surgery at the University of Pittsburgh and breast surgical oncologist at UPMC Hillman Cancer Center and UPMC Magee-Womens Hospital led a multidisciplinary team that developed and evaluated a novel #EHR nudge that reminds surgeons to consider the value of #SLNB in patients who are flagged as potentially eligible to forgo the surgery based on their age and tumor biology. In a study published today in JAMA Surgery, McAuliffe advocates for a shift towards ‘right-sized care’—a customized approach to treating each breast cancer patient with meticulous precision. The novel prompt was aided by #AI technology from Realyze Intelligence, which is a UPMC Enterprises portfolio company. More details: https://lnkd.in/eExUVthg

Researchers from University of Pittsburgh and UPMC Hillman Cancer Center are harnessing cutting-edge #AI technology developed by Realyze Intelligence, a UPMC Enterprises portfolio company, to revolutionize the field of precise surgical decision-making. The latest breakthrough? ➡ An electronic prompt or ‘digital nudge’ integrated within the electronic health record (EHR) system, aimed at reducing the overtreatment of breast cancer. The multidisciplinary team highlighted in JAMA Surgery today included Adrian Lee, Director, Institute for Precision Medicine among other UPMC and Pitt Research experts. Congratulations! ⬇ https://lnkd.in/eeWeGGK8

IPM Director, Adrian Lee is part of the multidisciplinary team from UPMC Hillman Cancer Center and University of Pittsburgh School of Medicine that developed and evaluated a novel #EHR nudge that reminds surgeons to consider the value of #SLNB in patients who are flagged as potentially eligible to forgo the surgery based on their age and tumor biology. In a study published today in JAMA Surgery, experts advocate for a shift toward 'right-sized care' - a customized approach to treating breast cancer with #precision. The novel prompt was aided by Realyze Intelligence #AI technology. Learn more ⬇ ⬇

➡ Researchers from University of Pittsburgh and UPMC Hillman Cancer Center are harnessing cutting-edge #AI technology developed by Realyze Intelligence, a UPMC Enterprises portfolio company, to revolutionize the field of precise surgical decision-making. JAMA Surgery Highlights ⬇

📑 📚 Publication Alert 📚 📑 We are thrilled to announce a new study, published today in JAMA Surgery, that showcases the powerful impact of Realyze Intelligence technology in transforming clinical data into actionable insights that improve patient care. 🔬 Key Highlights: - Researchers from the University of Pittsburgh and UPMC Hillman Cancer Center, aided by Realyze Intelligence, developed an innovative nudge embedded in electronic health records. - This nudge alerts surgeons about older patients with early-stage breast cancer who might be at risk of unnecessary surgery, significantly reducing overtreatment. - The study showed a nearly 50% reduction in sentinel lymph node biopsy (SLNB) among eligible patients, with further reductions observed over an additional 6-month period. 💡 Why This Matters: - Overuse of SLNB in older patients often leads to complications like lymphedema, impacting quality of life without providing survival benefits. - The nudge ensures right-sized care, personalized to each patient's unique needs, ultimately enhancing patient outcomes. - This study is a testament to the power of AI in healthcare, transforming clinical data into actionable insights and bettering patient care. Kudos to our dedicated researchers and the multidisciplinary team, including Dr. Adrian Lee, Dr. Neil Carleton, our CMO Gilan El Saadawi, MD, PhD and all involved at UPMC, UPMC Hillman Cancer Center, Institute for Precision Medicine & Magee-Womens Research Institute & Foundation, for their relentless pursuit of excellence in precision breast cancer treatment. 🌟 Read more about this incredible work below : #HealthcareInnovation #BreastCancerInnovation #AIinHealthcare #AIforGood #AIOncology #AIinPrecisionMedicine #PersonalizedMedicine #RealyzeIntelligence #UPMC #UPMCHillmanCancerCenter

🗓 Mark your calendar & be sure to join the 12 federal agency-led "Community Conversations" on initiatives supporting the CancerX Moonshot ! #CancerXMoonshot #CancerXMoonshotAccelerator #AIOncology #AIinPrecisionOncology #ClinicalTrialInnovation

The American Society of Clinical Oncology (ASCO) has set six guiding principals for use of AI in Oncology :::: 👥 👀 Transparency – AI tools and applications should be transparent throughout their lifecycle. 💡 Informed Stakeholders – Patients and clinicians should be aware when AI is used in clinical decision-making and patient care. ⚖ Equity and Fairness – Developers and users of AI should protect against bias in AI model design and use and ensure access to AI tools in application. ☑ Accountability – AI systems must comply with legal, regulatory, and ethical requirements that govern the use of data. AI developers should assume responsibility for their AI systems, its decisions, and their adherence to legal, regulatory, and ethical standards. 🔐 Oversight and Privacy – Decision-makers should establish institutional compliance policies that govern the use of AI, including protections that guard clinician and patient autonomy in clinical decision-making and privacy of personal health information. 👤 🫶 Human-Centered Application – Human interaction is a fundamental element of health care delivery; AI does not eliminate the need for human interaction and should not be used as a substitute for sensitive interactions that require it. We applaud ASCO for being at the forefront of setting this type of guidance! The Realyze Intelligence solution fits the bill - we support & adhere to all six of these guiding principals ✅ ✅ ✅ ✅ ✅ ✅ We're ready to help you accelerate clinical trial screening & turbocharge your clinical research. https://lnkd.in/gp3-MH7h #AIOncology #AIinPrecisionOncology #ClinicalTrialInnovation #NoMoreZombieTrials #RealyzeIntelligence

❗❗❗Just Released❗❗❗ The FDA has issued Draft Guidance on Diversity Action Plans for Clinical Studies - “Participants in clinical trials should be representative of the patients who will use the medical products,” said FDA Commissioner Robert M. Califf, M.D. “The agency’s draft guidance is an important step—and one of many ongoing efforts.” At Realyze Intelligence, we believe in an oncology future where clinical trial participation is the standard of care and a future where *ALL* cancer patients are proactively screened for clinical trial participation. ❓ Did you know that less than 15% of oncology clinical trial participants are minorities? In a joint research statement, ASCO & ACCC, have made a recommendation that *every* cancer patient be proactively screened for clinical trials to help combat the complex causes of inequity. Sound daunting or unfeasible? WE CAN HELP. ✅ The Realyze Intelligence platform drives inclusivity in clinical trials by enabling broader screening with existing resources. See below for examples on how our technology can drive inclusivity in clinical trials & equity in patient care. Read FDA press release : https://lnkd.in/eT5AhNTP Read FDA Draft Guidance : https://lnkd.in/gNczUwNA #ClinicalTrialsforAll #ClinicalTrialDiversity #AIOncology #AIinPrecisionMedicine #FDADraftGuidance #ClinicalTrialInnovation #CloseTheCareGap #RealyzeIntelligence